TScan Therapeutics, Inc.
NASDAQ:TCRXBiotechnology
+$0.02 today
- Market cap
- $50.37M
- Beta
- 1.03
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.96
Volume 0.00M
Average 0.81M
TCRX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
TScan Therapeutics, Inc.NASDAQ: TCRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $28.67M (cash outflow) fell 16.0% year over year, behind the -5.5% change in trailing-twelve-month net income. Sequentially, it rose 24.8% from the prior quarter. Over 3 fiscal years it compounded at +25.1% a year.
Context
- Net income amounted to 1256.8% of revenue in FY2025, down 3270.8 pp from a year earlier.
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 4 analysts of -$115.07M (-11.3%) for the fiscal year ending Dec 2026, a slowdown from the +1.8% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$28.67M+24.8% QoQ
- Last fiscal yearDec 2025
- -$129.77M+1.8% YoY
- LTMMar 2026
- -$124.31M-5.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -16.0% | -8.6% | +7.4 pp |
| 1 year | +1.8% | -11.3% | -13.1 pp |
| 3-year CAGR | +25.1% | -0.6% | -25.8 pp |
| 5-year CAGR | -16.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (129.77M) USD
- Year-over-year change
- -1.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (129.77M) | -1.8% |
| FY2024 | 2024-12-31 | (127.5M) | -42.9% |
| FY2023 | 2023-12-31 | (89.22M) | -34.7% |
| FY2022 | 2022-12-31 | (66.22M) | -36.2% |
| FY2021 | 2021-12-31 | (48.63M) | — |
Net Income vs competitors
How TCRX compares with its peers on the latest reported figures
- TCRX's LTM Mar 2026 net income of $124.31M is the largest of the 10 companies compared; the peer median is $58.88M.
- Its year-over-year change of -5.5% is the 6th highest of 10, against a peer median of +1.9%.
- Net income amounts to 1360.6% of revenue for TCRX, versus a peer median of 154.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $124.31M | -5.5% | +25.1% | 1360.6% | |
| LTM Mar 2026 | $108.83M | -7.2% | +18.7% | — | |
| LTM Mar 2026 | $104.29M | +8.2% | -6.9% | — | |
| LTM Mar 2026 | $102.15M | +215.2% | -46.4% | 154.4% | |
| LTM Mar 2026 | $78.34M | +28.7% | +2.0% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $77.27M | -7.7% | +35.7% | — |
| LTM Mar 2026 | $58.88M | -22.2% | -28.5% | — | |
| LTM Mar 2026 | $40.16M | +1.9% | +11.4% | — | |
| LTM Mar 2026 | $37.1M | +163.8% | — | 14.5% | |
| LTM Apr 2026 | $8.08M | -19.0% | +22.4% | 448.4% | |
| Peer median (excluding TCRX) | $58.88M | +1.9% | +6.7% | 154.4% | |
Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.63M) | (66.22M) | (89.22M) | (127.5M) | (129.77M) |
| Depreciation & Amortization | 3.33M | 5.14M | 5.36M | 4.11M | 2.87M |
| Deferred Income Tax | (9.16M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.52M | 4.55M | 5.21M | 9.55M | 11.71M |
| Change in Working Capital | (5.9M) | (10.23M) | 17.61M | 5.05M | (18.18M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 10K | 528K | (52K) | 1.99M | (3.01M) |
| Other Working Capital | (5.91M) | (10.76M) | 17.66M | 3.06M | (15.17M) |
| Other Non-Cash Items | 9.16M | 260K | (315K) | (2.03M) | (1.95M) |
| Operating Cash Flow | (48.68M) | (66.5M) | (61.36M) | (110.82M) | (135.32M) |
| Capital Expenditures | (9.94M) | (4.23M) | (3.15M) | (3.83M) | (4.41M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (77.61M) | (241.45M) | (87.47M) |
| Sales of Investments | 0 | 0 | 20M | 192.66M | 201.25M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (9.94M) | (4.23M) | (60.76M) | (52.61M) | 109.37M |
| Debt Repayment | 0 | 29.35M | 0 | 15.31M | 0 |
| Common Stock Issued | 89.65M | 193K | 42.41M | 33.13M | 264K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 291K | (191K) | 93.03M | 160.32M | (600K) |
| Financing Cash Flow | 189.67M | 29.36M | 135.44M | 208.77M | (336K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 131.05M | (41.37M) | 13.33M | 45.33M | (26.28M) |
| Free Cash Flow | (58.62M) | (70.73M) | (64.5M) | (114.65M) | (139.73M) |
TScan Therapeutics, Inc.
NASDAQ:TCRX
Intrinsic Alpha fair value
Locked
Current Price
$0.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.